NR1H4 and metabolic dysfunction-associated steatohepatitis: Ijssennagger et al. generated gene expression profiles in human PCLSs after treatment with Obeticholic acid (OCA), a promising drug for the treatment of MASH and type 2 diabetes that activates the farnesoid X receptor (FXR), a nuclear receptor regulating bile acid, glucose, and cholesterol homeostasis [208].